MetaStat, Inc. MTST

Company Overview

MetaStat, Inc. (OTC: MTST) is a healthcare and biotechnology company historically focused on cancer diagnostics and predictive medicine technologies related to metastatic disease. Public disclosures and historical investor materials describe the company’s efforts to develop blood-based and tissue-based diagnostic tools intended to help physicians assess the likelihood of cancer metastasis, particularly in breast cancer and other solid tumors. The company has operated within the broader biotechnology, precision medicine, and oncology diagnostics industries.

The company’s primary business focus has centered on proprietary diagnostic platforms and biomarker-driven technologies designed to support clinical decision-making in oncology. Publicly available filings indicate that MetaStat sought to differentiate itself through predictive analytics related to metastatic progression rather than traditional cancer detection alone. Historical records indicate the company evolved from early-stage research and intellectual property development into efforts aimed at commercialization and clinical validation. However, publicly available operational and financial disclosures have been limited in recent years, and some aspects of the company’s current activities and commercial scale remain difficult to independently verify.